Adalimumab-containing pharmaceutical composition

A composition and drug technology, applied in the field of pharmaceutical compositions containing adalimumab, can solve problems such as the safety impact of biopharmaceuticals, patient death, and reduced efficacy of biopharmaceuticals, achieve broad market application prospects, improve stability, high stability effect

Active Publication Date: 2015-06-17
HISUN BIOPHARMACEUTICAL CO LTD +1
View PDF7 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These degradation products will have a great impact on the safety of biopharmaceuticals
In particular, some protein aggregates can stimulate th

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adalimumab-containing pharmaceutical composition
  • Adalimumab-containing pharmaceutical composition
  • Adalimumab-containing pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment 1 Stability Study (1)

[0029] Biopharmaceuticals will experience various destructive conditions during production, transportation, storage and use, such as high temperature, light and freeze-thaw. To be safe, they must be able to maintain structural integrity, especially higher-level structures. Aggregates and insoluble particles of biopharmaceuticals are very critical factors that cause immune responses to biopharmaceuticals. The appearance of biopharmaceuticals is also a very important indicator. Pharmacopoeias of various countries stipulate that biological drugs must be free of visible foreign matter, because the presence or absence and content of particles in biological drugs are directly related to the safety of biological drugs, and they are considered to be one of the most important factors that cause the immune response of biological drugs.

[0030] SEC-HPLC is an analytical method that uses the relative relationship between the pore size of the ge...

Embodiment 2

[0060] Embodiment 2 stability study (two)

[0061] We have designed several preparation prescriptions 5-9, combined with the experimental results of preparation 2 and preparation 4 in Example 1, compared the freeze-thaw stability of the preparations with mannitol, sucrose and trehalose at different concentrations of adalimumab Among them, these preparations do not contain sodium chloride, and the other components in the preparation are: 0.35mg / ml sodium citrate, 1.3mg / ml citric acid, 0.86mg / ml sodium dihydrogen phosphate, 1.53mg / ml Disodium hydrogen phosphate, 1 mg / ml polysorbate 80, pH value of the solution is 5.2. The prescriptions of these preparations were frozen at -20°C for 5 hours, thawed at 4°C for 10 hours, and tested by SEC-HPLC after repeated freezing and thawing 8 times. The results are shown in Table 6.

[0062] Table 6 Effects of mannitol, sucrose and trehalose on the freeze-thaw stability of formulations under different adalimumab concentrations

[0063]

...

Embodiment 3

[0065] Embodiment 3: the preparation of low concentration (1mg / ml) and high concentration (100mg / ml) adalimumab preparation of sucrose and trehalose as structural protection agent

[0066] We designed and formulated formulations 10-13 containing low (1 mg / ml) and high (100 mg / ml) concentrations of adalimumab, respectively (Table 7), for validation of sucrose and trehalose as structural protectors Ability to formulate low and high concentration adalimumab formulations. These preparations do not contain sodium chloride, other components are: 0.35mg / ml sodium citrate, 1.3mg / ml citric acid, 0.86mg / ml sodium dihydrogen phosphate, 1.53mg / ml disodium hydrogen phosphate, 1mg / ml polysorbate 80, the solution pH value is 5.2.

[0067] Table 7 Preparations containing high and low concentrations of adalimumab with sucrose and trehalose as structural protective agents

[0068]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Login to view more

Abstract

Disclosed is a pharmaceutical composition comprising adalimumab and a structural protective agent, wherein the structural protective agent is selected from sucrose or trehalose, and the pharmaceutical composition has a high stability.

Description

technical field [0001] The invention belongs to the field of biotechnology, in particular to a pharmaceutical composition containing adalimumab. Background technique [0002] Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by joint synovitis. Long-lasting and repeated synovitis can lead to the destruction of cartilage and bone in the joint, joint dysfunction, and even disability. Vasculitis lesions involving various organs of the body, so the disease is also known as rheumatoid disease. About 80% of the patients have the age of onset between 20 and 45 years old, most of them are young adults, and the ratio of male to female is 1:2 to 4. There are 355 million people with photoarthritis worldwide. In Asia, 1 in 6 people will suffer from arthritis, the world's number one disabling disease, at some point in their lives. At present, it is estimated that there are more than 100 million arthritis patients in mainland China, and the number is sti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K47/26A61K39/395A61P29/00A61P19/02A61P17/06A61P19/08A61P1/00
CPCA61K39/39591A61P1/00A61P17/06A61P19/02A61P19/08A61P29/00A61P37/00C07K16/24A61K39/395A61K47/26
Inventor 方伟杰裘敏虹黄春辉王诏郑洪健王海彬应跃斌白骅
Owner HISUN BIOPHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap